Anavex Life Sciences +24% Premarket @$6.50; May be Attributed to Report on Australian Alzheimer's Trial

by Charles Gross, Benzinga Editor

April 25, 2016 7:08 AM | 0 seconds read | Make a Comment

http://www.9news.com.au/national/2016/04/24/19/51/alzheimers-breakthrough-in-melbourne-drug-trial#dfSrjdAC1puZClCF.99

Posted In: News Pre-Market Outlook Movers

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.